A specific pancreatic lipase inhibitor, orlistat, has been clinically used for the prevention of obesity [5–6] and many fields of research have focused on developing anti-obesity therapeutics with more efficiency and less side effect. This evidence concerns the gene PNLIP and obesity disorder.